Gilead’s Trodelvy gains EU regulatory momentum, but the first-line TNBC fight is only beginning
Gilead’s Trodelvy may move earlier in metastatic TNBC. The EU signal could reshape first-line ADC use, but adoption questions remain.
Marengo’s Invikafusp alfa shows early promise in metastatic breast cancer with dual-immunotherapy and ADC combination
Marengo Therapeutics has presented early-stage results from its STARt-002 clinical trial evaluating invikafusp alfa (Invika), a novel T cell immunotherapy candidate, in combination with sacituzumab govitecan (TRODELVY), an antibody-drug conjugate developed by Gilead Sciences. The data, shared during a late-breaking presentation at the 2025 San Antonio Breast Cancer Symposium, highlight the safety, pharmacodynamic activity, and […]